TN2014000195A1 - 2-thiopyrimidinones - Google Patents

2-thiopyrimidinones

Info

Publication number
TN2014000195A1
TN2014000195A1 TNP2014000195A TN2014000195A TN2014000195A1 TN 2014000195 A1 TN2014000195 A1 TN 2014000195A1 TN P2014000195 A TNP2014000195 A TN P2014000195A TN 2014000195 A TN2014000195 A TN 2014000195A TN 2014000195 A1 TN2014000195 A1 TN 2014000195A1
Authority
TN
Tunisia
Prior art keywords
inhibitors
thiopyrimidinones
myeloperoxidase
treating
pharmaceutical compositions
Prior art date
Application number
TNP2014000195A
Other languages
English (en)
Inventor
Philip Albert Carpino
Edward Lee Conn
Matthew Scott Dowling
David Hepworth
Daniel Wei-Shung Kung
Suvi Tuula Marjukka Orr
Benjamin Neil Rocke
Roger Benjamin Ruggeri
Joseph Scott Warmus
Yan Zhang
Matthew Forrest Sammons
Robert Lee Dow
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47356235&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000195(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of TN2014000195A1 publication Critical patent/TN2014000195A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Des inhibiteurs de la myéloperoxydase, des compositions pharmaceutiques contenant de tels inhibiteurs et l'utilisation de tels inhibiteurs pour traiter, par exemple, les affections cardiovasculaires.
TNP2014000195A 2011-11-11 2014-05-02 2-thiopyrimidinones TN2014000195A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558605P 2011-11-11 2011-11-11
PCT/IB2012/055949 WO2013068875A1 (fr) 2011-11-11 2012-10-28 2-thiopyrimidinones

Publications (1)

Publication Number Publication Date
TN2014000195A1 true TN2014000195A1 (fr) 2015-09-30

Family

ID=47356235

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2014000195A TN2014000195A1 (fr) 2011-11-11 2014-05-02 2-thiopyrimidinones

Country Status (34)

Country Link
US (4) US8835449B2 (fr)
EP (1) EP2776405A1 (fr)
JP (1) JP5731718B2 (fr)
KR (1) KR101650262B1 (fr)
CN (1) CN103917529B (fr)
AP (1) AP2014007621A0 (fr)
AR (1) AR088805A1 (fr)
AU (1) AU2012335220B2 (fr)
BR (1) BR112014011254A2 (fr)
CA (1) CA2853024C (fr)
CL (1) CL2014000996A1 (fr)
CO (1) CO6960543A2 (fr)
CR (1) CR20140179A (fr)
CU (1) CU20140049A7 (fr)
DO (1) DOP2014000098A (fr)
EA (1) EA027324B1 (fr)
EC (1) ECSP14004595A (fr)
GE (1) GEP201706656B (fr)
GT (1) GT201400090A (fr)
HK (1) HK1196603A1 (fr)
IL (2) IL232425A (fr)
MA (1) MA35638B1 (fr)
MD (1) MD20140044A2 (fr)
MX (1) MX351299B (fr)
NI (1) NI201400042A (fr)
PE (1) PE20161219A1 (fr)
PH (1) PH12014501032A1 (fr)
SG (1) SG11201401531RA (fr)
TN (1) TN2014000195A1 (fr)
TW (2) TWI526433B (fr)
UA (1) UA108713C2 (fr)
UY (1) UY34442A (fr)
WO (1) WO2013068875A1 (fr)
ZA (1) ZA201403589B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (fr) 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
AP2014007621A0 (en) * 2011-11-11 2014-05-31 Pfizer 2-Thiopyrimidinones
EP2592078A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
BR112015013628A2 (pt) 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
TN2017000461A1 (en) * 2015-05-05 2019-04-12 Pfizer 2-thiopyrimidinones
AR113826A1 (es) 2017-11-02 2020-06-17 Aicuris Gmbh & Co Kg Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20240166642A1 (en) 2022-08-18 2024-05-23 Astrazeneca Ab Inhibitors of myeloperoxidase

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088751A (en) 1972-04-07 1978-05-09 Colgate-Palmolive Company Self-heating cosmetic
US4171429A (en) 1977-03-29 1979-10-16 Research Corporation Pyrimidine to pyrimidine transformation process
EP0028489B1 (fr) 1979-11-05 1983-10-05 Beecham Group Plc Dérivés d'enzymes et leur préparation
JPS5770693A (en) 1980-10-22 1982-05-01 Fuji Photo Film Co Ltd Desensitizing composition
WO1989010701A1 (fr) 1988-05-05 1989-11-16 Basf Aktiengesellschaft Produits a base de derives d'uracil pour stimuler la croissance et reduire la graisse chez les animaux
KR0155168B1 (ko) 1989-09-29 1998-11-16 미우라 아끼라 6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제
JPH0699170B2 (ja) 1990-01-19 1994-12-07 日東紡績株式会社 耐火被覆材
JPH0525144A (ja) 1991-04-15 1993-02-02 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
JPH0525142A (ja) 1991-07-12 1993-02-02 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
JPH0543555A (ja) 1991-08-13 1993-02-23 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
TW284688B (fr) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
JPH063761A (ja) 1992-06-19 1994-01-14 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
KR0151811B1 (ko) 1993-12-21 1998-10-15 강박광 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법
JP3781200B2 (ja) 1994-04-27 2006-05-31 コニカミノルタホールディングス株式会社 ハロゲン化銀写真感光材料の処理方法
JP3261641B2 (ja) 1994-04-28 2002-03-04 コニカ株式会社 ハロゲン化銀写真感光材料の処理方法
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
EE9700209A (et) 1994-11-16 1998-04-15 Synaptic Pharmaceutical Corporation Dihüdropürimidiinid ja nende kasutamine
WO1997017969A1 (fr) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropirimidines et leurs emplois
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US5719190A (en) 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
JP2000506904A (ja) 1996-05-16 2000-06-06 シナプティック・ファーマスーティカル・コーポレーション ジヒドロピリミジン類およびその使用
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
WO1998024780A2 (fr) 1996-12-05 1998-06-11 Amgen Inc. Composes substitues a base de pyrimidone et de pyridone et procedes d'utilisation
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
ES2199366T3 (es) 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE19731784A1 (de) 1997-07-24 1999-02-04 Bayer Ag Substituierte N-Aryl-N-thioxocarbonyl-sulfonamide
US6130340A (en) 1998-01-13 2000-10-10 President And Fellows Of Harvard College Asymmetric cycloaddition reactions
US6211370B1 (en) 1998-01-13 2001-04-03 Harvard University Asymmetric cycloaddition reactions
WO1999059561A2 (fr) 1998-05-18 1999-11-25 Hensley, Kenneth, L. Inhibition de myeloperoxydase par du resveratrol
DE69940063D1 (de) 1998-07-06 2009-01-22 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
CA2252144A1 (fr) 1998-10-16 2000-04-16 University Of Alberta Prodrogues anticancer a action double
DE19918725A1 (de) 1999-04-24 2000-10-26 Bayer Ag Substituierte N-Cyano-sulfonsäureanilide
ATE432265T1 (de) * 1999-05-01 2009-06-15 Smithkline Beecham Plc Pyrimidinon verbindungen
HUP0201404A3 (en) 1999-06-02 2005-02-28 Janssen Pharmaceutica Nv Aminoalkyl substituted benzodioxan, benzofuran or benzopyran derivatives, pharmaceutical compositions containing them and their use and process for their preparations
IT1307786B1 (it) * 1999-07-22 2001-11-19 Bracco Spa Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
JP2001131133A (ja) 1999-08-23 2001-05-15 Sankyo Co Ltd 新規ミエロペルオキシダーゼ阻害物質およびその製造方法
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
GB2362101A (en) 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
GB0013655D0 (en) 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
JO2352B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Compounds for the treatment of non-adaptation of the bottom of the uterus
JP2004504303A (ja) 2000-07-05 2004-02-12 シナプティック・ファーマスーティカル・コーポレーション 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
WO2002006389A2 (fr) 2000-07-14 2002-01-24 Akzo Nobel N.V. Systeme stabilisateur comprenant des hydroxyacides
DE10034800A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Benzostickstoffheterocyclen
DE10034803A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Sulfonsäureanilide
WO2003011799A1 (fr) 2000-07-31 2003-02-13 Brandeis University Resolutions par voie cinetique composes chiraux d'acides carboxyliques substitues en position 2 et en position 3
US6562967B2 (en) 2000-07-31 2003-05-13 Brandeis University Kinetic resolutions of chiral 2-and-3-substituted carboxylic acids
WO2002010096A1 (fr) 2000-07-31 2002-02-07 Brandeis University Résolutions cinétiques d'acides carboxyliques chiraux 2- et 3-substitués
EP2180064A3 (fr) 2000-10-18 2010-08-11 Pharmasset, Inc. Quantification multiplex d'acides nucléiques dans des cellules malades
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
DE10108995A1 (de) 2001-02-23 2002-09-05 Abbott Gmbh & Co Kg Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
WO2002069903A2 (fr) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, leur preparation et utilisation en tant qu'inhibiteurs de polymerases virales d'arn
DK1387893T3 (da) 2001-05-08 2007-02-19 Astrazeneca Ab Assay til detektion af inhibitorer af enzymet myeloperoxidase
KR20100087209A (ko) 2001-08-10 2010-08-03 시오노기세이야쿠가부시키가이샤 항바이러스제
US20040106626A1 (en) 2001-10-03 2004-06-03 Pharmacia Corporation 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
WO2003028729A2 (fr) 2001-10-03 2003-04-10 Pharmacia Corporation Promedicaments de composes polycycliques substitues utiles pour l'inhibition selective de la cascade de la coagulation
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
MXPA04003170A (es) 2001-10-03 2004-07-08 Pharmacia Corp Compuestos policiclicos, sustituidos, provisto de 5 miembros, utiles para la inhibicion selectiva de la cascada de coagulacion.
WO2003057677A1 (fr) 2002-01-11 2003-07-17 Syddansk Universitet Derives de 5,6-bisubstitue acyclopyrimidine nucleoside a activite antiretrovirale
EA200400980A1 (ru) 2002-02-27 2005-02-24 Пфайзер Продактс Инк. Ингибиторы асс
US20030232813A1 (en) 2002-04-10 2003-12-18 Orchid Chemicals & Pharmaceuticals Limited Novel amino substituted pyrimidinone derivatives
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
JP4623279B2 (ja) 2002-05-16 2011-02-02 メリアル・リミテッド ピリジンカルボキサミド誘導体および農薬としてのその使用
EP1394242A3 (fr) 2002-08-07 2004-04-21 Rohm And Haas Company Thiourées cycliques et leur utilisation en tant qu'additifs pour huiles lubrifiantes
EP1394241A1 (fr) 2002-08-07 2004-03-03 Rohm And Haas Company Thioureas comme additifs pour huiles lubrifiantes
WO2004037159A2 (fr) 2002-10-23 2004-05-06 Obetherapy Biotechnology Composes, compositions et methodes permettant de moduler le metabolisme des graisses
US20050096319A1 (en) 2003-02-21 2005-05-05 Balzarini Jan M.R. Identification of compounds that inhibit replication of human immunodeficiency virus
EP1603546A1 (fr) 2003-02-21 2005-12-14 Tripep AB Derive du glycinamide destine a inhiber la replication du vih
CA2521606A1 (fr) 2003-04-07 2004-10-21 Cortical Pty Ltd. Nouvelles methodes de traitement des maladies inflammatoires
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
US7485604B2 (en) 2003-05-27 2009-02-03 Fujifilm Corporation Lubricant composition and method for using and preparing thereof
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
US7947817B2 (en) 2003-06-30 2011-05-24 Roche Molecular Systems, Inc. Synthesis and compositions of 2'-terminator nucleotides
EP1706405B1 (fr) 2003-12-22 2009-03-04 Gilead Sciences, Inc. Derives de carbovir et d'abacavir 4'-substitues et composes associes dotes d'une activite antivirale dirigee contre le vih et le vhc
CA2559302C (fr) 2004-03-15 2012-06-19 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyle peptidase
WO2005116014A1 (fr) 2004-05-12 2005-12-08 Pfizer Products Inc. Derives de proline et leur utilisation en tant qu'inhibiteurs de la dipeptidyl-peptidase iv
US7745125B2 (en) 2004-06-28 2010-06-29 Roche Molecular Systems, Inc. 2′-terminator related pyrophosphorolysis activated polymerization
US7928207B2 (en) 2004-06-28 2011-04-19 Roche Molecular Systems, Inc Synthesis and compositions of nucleic acids comprising 2′-terminator nucleotides
EP1616874A1 (fr) 2004-07-14 2006-01-18 Universiteit Gent Composés mono- et bicycliques à activité thérapeutique et compositions pharmaceutiques les comprenant
EP1778778A4 (fr) 2004-08-12 2011-04-27 King Industries Inc Compositions organometalliques et compositions de revetement
US7485729B2 (en) 2004-08-12 2009-02-03 King Industries, Inc. Organometallic compositions and coating compositions
WO2006031806A2 (fr) 2004-09-10 2006-03-23 Atherogenics, Inc. 2-thiopyrimidinones utilises en tant qu'agents therapeutiques
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006070292A2 (fr) 2004-10-12 2006-07-06 Queen's University At Kingston Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou agents anti-epileptogeniques
SE0402591D0 (sv) 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP1731911A1 (fr) 2005-06-07 2006-12-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procédé utile pour la détection d'encéphalopathies
US7399786B2 (en) 2005-06-30 2008-07-15 Bexel Pharmaceuticals, Inc. Derivatives of amino acids for treatment of obesity and related disorders
US20100105145A1 (en) 2005-07-01 2010-04-29 Dako Denmark A/S Method of simultaneously visualizing multiple biological targets
DE602006020577D1 (de) 2005-07-01 2011-04-21 Dako Denmark As Monomere und polymere linker zur konjugierung von biologischen molekülen und anderen stoffen
EP1948638B1 (fr) 2005-08-12 2011-08-03 Schering Corporation Composes pour traiter des maladies inflammatoires
WO2007064797A2 (fr) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
MEP7609A (en) 2005-12-28 2011-12-20 Therapeutic agent for diabetes
DE102006000649A1 (de) 2006-01-03 2007-07-05 Degussa Gmbh Universell einsetzbare Zusammensetzungen
DE102006000651A1 (de) 2006-01-03 2007-07-12 Degussa Gmbh Präparation aus Ionischen Flüssigkeiten und Harzen
JP5025142B2 (ja) 2006-02-27 2012-09-12 株式会社東芝 モータ制御装置
JP5025144B2 (ja) 2006-02-28 2012-09-12 Ｊｘ日鉱日石エネルギー株式会社 内燃機関用潤滑油組成物
UY30267A1 (es) 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
PT2463283E (pt) 2006-04-20 2014-08-27 Pfizer Prod Inc Compostos heterocíclicos de fenil amido condensados para a prevenção e tratamento de doenças mediadas pela glucoquinase
TW200808649A (en) 2006-05-31 2008-02-16 Du Pont Process for purifying perfluorinated products
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
WO2007142577A1 (fr) 2006-06-05 2007-12-13 Astrazeneca Ab Dérivé de pyrrolo[3,2-d]pyrimidine-4-un en tant qu'inhibiteur de la myéloperoxydase
JP5255441B2 (ja) 2006-08-04 2013-08-07 富山化学工業株式会社 アルキルエーテル誘導体またはその塩を含有するプロテインキナーゼｃ活性促進剤
WO2008023249A1 (fr) 2006-08-24 2008-02-28 Chemfit Speciality Chemicals (Pty) Ltd Composition de poly(chlorure de vinyle)
EP2097405A2 (fr) 2006-11-21 2009-09-09 Smithkline Beecham Corporation Composés anti-viraux
EA200900613A1 (ru) 2006-11-29 2009-10-30 Пфайзер Продактс Инк. Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
US20080153697A1 (en) 2006-12-22 2008-06-26 E. I. Dupont De Nemours And Company Mixtures of ammonia and ionic liquids
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
CN101784532B (zh) 2007-06-29 2014-10-22 韩国化学研究院 Hiv逆转录酶抑制剂
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
JP5043555B2 (ja) 2007-08-08 2012-10-10 株式会社カネカ 硬化性組成物
US20090054468A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US20090053176A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab New Combination 937
BRPI0817897A2 (pt) 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
GB0722680D0 (en) 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use
JP2009167179A (ja) 2007-12-21 2009-07-30 Daiichi Sankyo Co Ltd 環状アミン化合物を含有する医薬
EP2268616A1 (fr) 2008-03-21 2011-01-05 Chlorion Pharma, Inc. Composés de pyrrolidine et de pipéridine substitués, leurs dérivés et procédés de traitement de la douleur
WO2009120872A2 (fr) 2008-03-26 2009-10-01 Ada Technologies, Inc. Batteries de haute performance avec nanomatériaux de carbone et liquides ioniques
US8415321B2 (en) 2008-04-15 2013-04-09 Raymond F. Schinazi Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections
US8277691B2 (en) 2008-05-05 2012-10-02 Ada Technologies, Inc. High performance carbon nanocomposites for ultracapacitors
CA2724603A1 (fr) 2008-05-28 2009-12-03 Pfizer Inc. Inhibiteurs de la pyrazolospirocetone acetyl-coa carboxylase
US8318762B2 (en) 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
JP4825322B1 (ja) 2008-08-28 2011-11-30 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
GB0818063D0 (en) * 2008-10-02 2008-11-05 Univ Dundee Compounds
JP5206367B2 (ja) 2008-11-27 2013-06-12 コニカミノルタエムジー株式会社 ウレア化合物を含む有機圧電材料
WO2010086820A1 (fr) 2009-02-02 2010-08-05 Pfizer Inc. Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
SI2406253T1 (sl) 2009-03-11 2013-09-30 Pfizer Inc. Derivati benzofuranila, uporabljeni kot inhibitorji glukokinaze
CA2754685A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitues
EP2408780A2 (fr) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3,3.1¨nonanes
EP2424854A4 (fr) 2009-04-23 2012-10-17 Invasc Therapeutic Inc Compositions et procédés de traitement de maladie cardiovasculaire
WO2010124237A1 (fr) 2009-04-24 2010-10-28 Novabay Pharmaceuticals Inc. Méthodes de traitement d'infections unguéales
CA2759843A1 (fr) 2009-05-08 2010-11-10 Pfizer Inc. Modulateurs de gpr119
EP2427448A1 (fr) 2009-05-08 2012-03-14 Pfizer Inc. Modulateurs du gpr119
EP2435043A1 (fr) 2009-05-27 2012-04-04 Université Libre de Bruxelles Dérivés de 3-alkyl-5-fluoroindole en tant qu'inhibiteurs de peroxydase leucocytaire
WO2010138901A1 (fr) 2009-05-29 2010-12-02 Biogen Idec Ma Inc Composés contenant de l'acide carboxylique, leurs dérivés et procédés d'utilisation associés
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2010151711A1 (fr) 2009-06-25 2010-12-29 Alkermes, Inc. Promédicaments de composés nh acides
HRP20171415T4 (hr) 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
US9790252B2 (en) 2009-07-01 2017-10-17 Cornell University 2-fluorinated riboses and arabinoses and methods of use and synthesis
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
DE102009037300A1 (de) 2009-08-14 2011-02-17 Merck Patent Gmbh Tetracyanoborate als Schmierstoffe
WO2011045415A2 (fr) 2009-10-15 2011-04-21 Guerbet Nouveaux agents d'imagerie et leur utilisation pour le diagnostic in vivo de maladies neurodégénératives, notamment la maladie d'alzheimer et les maladies dérivées
WO2011057220A2 (fr) 2009-11-09 2011-05-12 Northwestern University Compositions et méthodes pour traiter les lymphomes
FR2953145B1 (fr) 2009-11-30 2013-07-19 Inst Francais Du Petrole Solution absorbante contenant un inhibiteur de degradation derive de la pyrimidine ou de la triazine et procede d'absorption de composes acides contenus dans un effluent gazeux
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
WO2011109799A1 (fr) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
EP2585066B1 (fr) 2010-06-24 2018-09-26 Alkermes Pharma Ireland Limited Promédicaments de composés nh-acides : dérivés esters, carbonates, carbamates et phosphonates
WO2012016133A2 (fr) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
ES2352926B1 (es) 2010-12-07 2012-01-12 Universidad De Granada Fenucil deuterado y derivados, procedimiento para su preparación y usos de los mismos.
AP2014007621A0 (en) * 2011-11-11 2014-05-31 Pfizer 2-Thiopyrimidinones
JP6003761B2 (ja) 2013-03-27 2016-10-05 富士ゼロックス株式会社 送風管、送風装置及び画像形成装置
TN2017000461A1 (en) * 2015-05-05 2019-04-12 Pfizer 2-thiopyrimidinones

Also Published As

Publication number Publication date
WO2013068875A1 (fr) 2013-05-16
EA027324B1 (ru) 2017-07-31
ZA201403589B (en) 2015-06-24
UY34442A (es) 2013-06-28
CR20140179A (es) 2014-06-12
CA2853024C (fr) 2017-08-22
SG11201401531RA (en) 2014-07-30
EP2776405A1 (fr) 2014-09-17
TWI526433B (zh) 2016-03-21
EA201490688A1 (ru) 2014-10-30
AU2012335220A1 (en) 2014-05-01
MX351299B (es) 2017-10-10
BR112014011254A2 (pt) 2017-05-16
US20140288049A1 (en) 2014-09-25
KR101650262B1 (ko) 2016-08-22
JP5731718B2 (ja) 2015-06-10
AU2012335220B2 (en) 2017-06-01
TW201332979A (zh) 2013-08-16
CN103917529B (zh) 2016-08-17
US20130123230A1 (en) 2013-05-16
US8841314B2 (en) 2014-09-23
CA2853024A1 (fr) 2013-05-16
AP2014007621A0 (en) 2014-05-31
DOP2014000098A (es) 2014-07-31
IL249039B (en) 2018-07-31
US9399626B2 (en) 2016-07-26
MD20140044A2 (ro) 2014-08-31
IL232425A0 (en) 2014-06-30
TW201518281A (zh) 2015-05-16
US20160304469A1 (en) 2016-10-20
US8835449B2 (en) 2014-09-16
TWI480269B (zh) 2015-04-11
CO6960543A2 (es) 2014-05-30
PE20161219A1 (es) 2016-11-17
JP2014533261A (ja) 2014-12-11
PH12014501032A1 (en) 2014-10-20
NI201400042A (es) 2014-10-01
AR088805A1 (es) 2014-07-10
GEP201706656B (en) 2017-04-25
NZ624453A (en) 2015-12-24
HK1196603A1 (zh) 2014-12-19
MA35638B1 (fr) 2014-11-01
UA108713C2 (xx) 2015-05-25
IL232425A (en) 2016-11-30
CN103917529A (zh) 2014-07-09
GT201400090A (es) 2015-09-04
IL249039A0 (en) 2017-01-31
ECSP14004595A (es) 2015-11-30
US9873673B2 (en) 2018-01-23
US20130296351A1 (en) 2013-11-07
MX2014005721A (es) 2014-05-28
CU20140049A7 (es) 2014-08-28
KR20140089603A (ko) 2014-07-15
CL2014000996A1 (es) 2014-07-04

Similar Documents

Publication Publication Date Title
TN2014000195A1 (fr) 2-thiopyrimidinones
PH12017501306A1 (en) Inhibitors of histone demethylases
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
EA201190224A1 (ru) Ингибиторы гепатита c, содержащие конденсированные кольца
MX2013004491A (es) Boronatos como inhibidores de arginasa.
EA201500362A1 (ru) Ингибиторы rho-киназы
MA34780B1 (fr) Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r human et leur utilisation
JO3363B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
BR112014028042A2 (pt) inibidores de nampt
MD3319967T2 (ro) Compuşi inhibitori ai căii de semnalizare Notch
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA33457B1 (fr) L-sérine pour son utilisation en tant que médicament pour prévenir et/ou traiter une réaction inflammatoire de la peau
GEP20156346B (en) Imidazole derivatives as pde10a enzyme inhibitors
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MX2014007969A (es) Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8.
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
PH12017501897A1 (en) 2-thiopyrimidinones
EA201690673A1 (ru) Комбинированная терапия лахинимодом для лечения рассеянного склероза
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز
PL399013A1 (pl) Pochodna 1,2,4-triazolu-5-(3-chlorofenylo)-4-nonylo-2,4-dihydro-3H-1,2,4-triazolo-3-tion, sposób jej wytwarzania i jej zastosowanie medyczne
FR2985256B1 (fr) Derives piperazinyles pour le traitement de cancers
MA38549A1 (fr) Activateur d'inhibiteurs de l'homologue 2 de zeste